$RDY News
Last published 3mo ago
- 3mo agoRDYTentative Approval of Bempedoic Acid, Anda #219312FDA Approved DrugsApproval Date: 08/06/2026; Drug Name: Bempedoic Acid, Anda #219312; Active Ingredients: BEMPEDOIC ACID; Company: Dr. Reddy's Laboratories Limited; Submission Status: Tentative Approval; Application Number: 219312
- 3mo agoRDYDr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United StatesBusiness WireDr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, along with its subsidiaries together referred to as "Dr. Reddy’s") today announced the launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL)
- 4mo agoRDYDr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-FBusiness WireDr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy’s") announced that its Annual Report in Form 20-F,
- 5mo agoRDYDr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United StatesBusiness WireDr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the first-to-market launch of Bosutinib Tablets 400mg, a generic
- 5mo agoRDYDr. Reddy's Laboratories Launches its Generic Semaglutide Injection in CanadaBusiness WireThe launch follows Dr. Reddy's receipt of the Notice of Compliance (NOC) from Health Canada on April 28th, 2026, marking the company's readiness to serve Canadian patients Dr. Reddy's is the first company to receive
- 6mo agoRDYTentative Approval of Palbociclib, Anda #220444FDA Approved DrugsApproval Date: 05/15/2026; Drug Name: Palbociclib, Anda #220444; Active Ingredients: PALBOCICLIB; Company: Dr. Reddy's Laboratories Limited; Submission Status: Tentative Approval; Application Number: 220444
- 6mo agoRDYDr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in CanadaBusiness WireDr. Reddy's becomes the first company to receive marketing authorization for generic Semaglutide Injection in Canada The market authorization was granted to Dr. Reddy's ahead of Health Canada's review target
- 8mo agoRDYDr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, AbataceptBusiness WireFollowing the submission in December 2025, USFDA has accepted Dr. Reddy's 351(k) Biologics License Application (BLA) for Proposed Interchangeable biosimilar Abatacept, DRL_AB (IV for Infusion) BLA is based on a
- 10mo agoRDYDr. Reddy's Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.Business WireDr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of over-the-counter (OTC) Olopatadine Hydrochloride
- 11mo agoIMMPRDYImmutep and Dr. Reddy's enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod AlfaGlobeNewswireDr. Reddy's receives exclusive rights to develop and commercialise Eftilagimod Alfa in all countries outside North America, Europe, Japan, and Greater China Under the terms, Immutep to receive upfront payment of USD 20
- 1y agoRDYAurigene Oncology to Showcase Innovative A-PROX Platform at the AACR-NCI-EORTC International Conference 2025Business WireAurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced that it will present new data from its proprietary Targeted Protein Degradation (TPD) and
- 1y agoCOYARDYCoya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)PR NewswireCoya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance ...
- 1y agoRDYExtrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S.GlobeNewswireExtrovis AGBahnhof Park 46340, Baar, SwitzerlandMedia Relations ContactMadhu Marurmadhu.marur@extrovis.com Press Release Extrovis AG and
- 1y agoRDYTentative Approval of Lumateperone, Anda #219229FDA Approved DrugsApproval Date: 08/06/2025; Drug Name: Lumateperone, Anda #219229; Active Ingredients: LUMATEPERONE; Company: Dr. Reddy's Laboratories Limited; Submission Status: Tentative Approval; Application Number: 219229
- 1y agoRDYDr. Reddy's Q1FY26 Financial ResultsBusiness WireDr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter ended June 30, 2025. The information mentioned in this release is
- 1y agoALVORDYAlvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)Business WireAlvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide ("Alvotech"), and Dr. Reddy's Laboratories Ltd., (BSE: 500124, NSE:
- 1y agoALVORDYAlvotech and Dr. Reddy's Enter into Collaboration to Co-Develop Biosimilar Candidate to Keytruda® (pembrolizumab)GlobeNewswireHYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide
- 1y agoRDYDr. Reddy's Q4 & Full Year FY25 Financial ResultsBusiness WireDr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and year ended March 31, 2025. The information mentioned in this
- 1y agoRDYBio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast AsiaPR NewswireBio-Thera Solutions (688177:SH; "Bio-Thera"), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and...
- 1y agoALVORDYAlvotech and Dr. Reddy's Announce FDA Acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®Business WireDr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's") and Alvotech (NASDAQ:ALVO), a global biotech company specializing
- 1y agoALVORDYAlvotech and Dr. Reddy's Announce FDA acceptance of Biologic License Application for AVT03, a Proposed Biosimilar to Prolia® and Xgeva®GlobeNewswireHYDERABAD, India and REYKJAVIK, Iceland, March 18, 2025 (GLOBE NEWSWIRE) -- Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr.
- 1y agoRDYDr. Reddy's Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., due to Mislabeling of Infusion BagBusiness WireDr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's"), is recalling one Batch/Lot No: A1540076 of Levetiracetam in 0.75%
- 1y agoRDYDr. Reddy's enters into collaboration with Henlius for commercialization of HLX15 (daratumumab), a biosimilar candidate to Darzalex® & Darzalex Faspro® in the U.S., and EuropeBusiness WireDr. Reddy's gets exclusive rights to commercialize the subcutaneous as well as intravenous formulations of HLX15 in the U.S. and Europe Dr. Reddy's Laboratories SA, wholly-owned subsidiary of Dr. Reddy's Laboratories
- 1y agoRDYHenlius and Dr. Reddy's Ink Licensing Deal for HLX15 (investigational daratumumab biosimilar) Expansion in Europe and the U.S.PR NewswireShanghai Henlius Biotech, Inc. (2696.HK) today announced it has entered into a license agreement with Dr. Reddy's Laboratories SA, wholly-owned...
- 1y agoRDYDr. Reddy's Q3 & 9MFY25 Financial ResultsBusiness WireDr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY) today announced its consolidated financial results for the quarter and nine months ended December 31, 2024. The information mentioned
- 1y agoRDYNovo Nordisk A/S vs DR. REDDY'S LABORATORIES, INC. et al. - AIA Trial, Settled After InstitutionUS Patent Trial and Appeal Board
- 1y agoRDYDr. Reddy's launches Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinomaBusiness WireOnly immuno-oncology drug approved by various regulatory authorities around the world such as the USFDA, DCGI, EMA, MHRA, NMPA and others for the treatment of adults with recurrent or metastatic nasopharyngeal
- 1y agoRDYDr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch of Ivermectin Tablets USP, 3 mg in US MarketBusiness WireDr. Reddy's Laboratories, Inc. and Senores Pharmaceuticals, Inc. today announced the launch of Ivermectin Tablets USP, 3 mg, which is bioequivalent and therapeutically equivalent to STROMECTOL® Tablets of Merck
- 2y agoRDYDr. Reddy's Laboratories Limited (RDY) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoRDYDr. Reddy's Q2 & H1FY25 Financial ResultsBusiness WireDr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the quarter and half year ended September 30, 2024. The information
- 2y agoRDYDr. Reddy's Named by Science Magazine in Top 20 Global Pharma Employers List for Third Consecutive YearBusiness WireDr. Reddy's Laboratories Ltd. ("Dr. Reddy's") has been ranked among the top employers according to the 2024 Top Biotech and Pharma Employers Survey conducted by Science. This marks the third consecutive appearance of
- 2y agoRDYDr. Reddy's Launches Comprehensive Menopause Support Program and Training for Employees During Menopause Awareness MonthBusiness WireDr. Reddy's Laboratories Inc., the U.S. arm of Dr. Reddy's Laboratories Ltd., a global pharmaceutical company headquartered in Hyderabad, India, today announced the launch of a comprehensive employee support program
- 2y agoRDYAurigene Oncology Limited Announces Promising Results of Phase 1 Study for India's First Trial for Novel Autologous CAR-T Cell Therapy for Multiple MyelomaBusiness WireAurigene Oncology Limited, a wholly-owned subsidiary of Dr. Reddy's Laboratories Limited and a clinical stage biotech committed to bringing in novel and effective therapeutics for the treatment of cancer, has announced
- 2y agoRDYDr. Reddy's signs voluntary licensing agreement with Gilead Sciences to manufacture and commercialise Lenacapavir in India and other countriesBusiness WireDr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")), today announced that it has entered into a royalty-free
- 2y agoRDYDr. Reddy's Laboratories, Aurigene Pharmaceutical Services, and Kainomyx Announce Potential Partnership for Joint Development of Affordable Anti-Malarial DrugBusiness WireMalaria is a life-threatening public health issue, particularly in low- and middle-income countries. There is a need for an effective, affordable, and accessible preventive and/or treatment medication. This potential
- 2y agoRDYDr. Reddy's Receives Positive CHMP Opinion From European Medicines Agency for Its Proposed Rituximab BiosimilarBusiness WireDr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as "Dr. Reddy's")), today announced that the European Medicines Agency's (EMA)
- 2y agoRDYDr. Reddy's Q1FY25 Financial ResultsBusiness WireDr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the quarter ended June 30, 2024. The information mentioned in this release
- 2y agoHLNRDYDr. Reddy's to Acquire Nicotinell and Related Portfolio in Significant Step Towards Building Global Consumer Healthcare BusinessBusiness WirePortfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to
- 2y agoRDYAurigene Pharmaceutical Services Limited, a Global CRDMO, Announces the Opening of Its Biologics Facility Offering Process Development and Clinical Scale Manufacturing CapabilitiesBusiness WireAurigene Pharmaceutical Services Limited ("Aurigene"), a Dr. Reddy's Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad,
- 2y agoRDYDr. Reddy's Laboratories Announces the Appointment of Milan Kalawadia to CEO North AmericaBusiness WireDr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as ", Dr. Reddy', s", )), today announced the appointment of Milan
- 2y agoALVORDYAlvotech and Dr. Reddy's Enter Into Collaboration for Commercialization of AVT03 (denosumab), a Biosimilar Candidate to Prolia® & Xgeva® in the U.S., Europe and UKBusiness WireDr. Reddy's gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and manufacture of the
- 2y agoALVORDYAlvotech and Dr. Reddy's enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UKGlobeNewswireDr. Reddy's gets exclusive commercialization rights in the United States (U.S.) as well as semi-exclusive rights in Europe and United Kingdom (UK) Alvotech will be responsible for development and manufacture of the
- 2y agoRDYDr. Reddy's Laboratories Limited (RDY) Q4 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoRDYDr. Reddy's Q4 & Full Year FY24 Financial ResultsBusiness WireDr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the fourth quarter and full year ended March 31, 2024. The information
- 2y agoRDYDr. Reddy's Laboratories Announces the Launch of Doxycycline Capsules, 40 mg* in the U.S.Business WireDr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as ", Dr. Reddy', s", )), today announced its launch of Doxycycline
- 2y agoRDYPharmazz Inc. and Dr. Reddy's Laboratories have entered into a licensing agreement to market Centhaquine (Lyfaquin) as a resuscitative agent for hypovolemic shock in IndiaGlobeNewswireCenthaquine is a first-of-its-kind resuscitative agent to treat hypovolemic shock by increasing stroke volume and cardiac output due to an increase in (preload) venous blood return to the heart and a decrease in
- 2y agoRDYDr. Reddy's Laboratories launches Versavo® (bevacizumab) in the UKBusiness WireVersavo® (bevacizumab) is indicated for the treatment of several types of cancers including metastatic colorectal cancer, advanced non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal
- 2y agoRDYDr. Reddy's Q3 & 9M FY24 Financial ResultsBusiness WireDr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY)) today announced its consolidated financial results for the quarter and nine months ended December 31, 2023. The information
- 2y agoRDYDr Reddy's Laboratories Ltd (RDY) Q3 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoRDYDr. Reddy's Announces the Acquisition of MenoLabs®, a Leading Women's Health and Dietary Supplements Portfolio of BrandsBusiness WireDr. Reddy's Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE:RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as ", Dr. Reddy', s", )), today announced that it has acquired